Table 3 HER2 immunohistochemistry score and HER2 FISH status according to histological urothelial carcinoma variants in primary tumors

From: Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility

Primary tumor

IHC ASCO/CAP 2013

FISH

Histological variant a

0 N (%)

1 N (%)

2 N (%)

3 N (%)

Eligible cases b N (%)

Contributive cases

Positive

Equivocal

Negative

Pure conventional urothelial carcinoma (N = 68)

22 (32)

7 (10)

37 (55)

2 (3)

15 (22)

15

4

5

6

UCB with squamous differentiation (N = 44)

19 (43)

3 (7)

19 (43)

3 (7)

12 (27)

12

5

3

4

UCB with glandular differentiation (N = 3)

1 (33)

0

2 (67)

0

2

2

2

0

0

Micropapillary carcinoma (N = 50)

7 (14)

10 (20)

30 (60)

3 (6)

30 (60)

25

6

7

12

Pure micropapillary carcinoma (N = 20)

1 (5)

4 (20)

14 (70)

1 (5)

15 (75)

13

3

5

5

Mixed micropapillary carcinoma (N = 30)

6 (20)

6 (20)

16 (53)

2 (7)

15 (50)

12

3

2

7

Plasmacytoid/single-cell carcinoma (N = 13)

3 (23)

3 (23)

7 (54)

0

3 (23)

2

0

1

1

Sarcomatoid carcinoma (N = 23)

15 (65)

2 (9)

6 (26)

0

3 (13)

3

2

0

1

Giant cell (N = 1)

0

0

1

0

1

0

.

.

.

Microcystic (N = 1)

1

0

0

0

0

0

.

.

.

  1. ASCO/CAP American Society of Clinical Oncology/College of American Pathologists, FISH fluorescent in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, UCB urothelial carcinoma of the bladder
  2. a Sum of percentages above 100% due to tumor heterogeneity
  3. b Eligible cases according to criteria applied in our study (moderate or strong, complete or incomplete membrane staining in ≥10% of cells)
Back to article page